Inhibition of the immunoproteasome LMP2 ameliorates ischemia/hypoxia-induced blood-brain barrier injury through the Wnt/β-catenin signalling pathway.
Xing-Yong ChenShao-Fen WanNan-Nan YaoZe-Jing LinYan-Guang MaoXiao-Hua YuYin-Zhou WangPublished in: Military Medical Research (2021)
This study suggests that inhibition of the immunoproteasome LMP2 ameliorates ischemia/hypoxia-induced BBB injury, and that the molecular mechanism involves the immunoproteasome-regulated activation of the Wnt/β-catenin signalling pathway under ischemic conditions.